Meadow Creek Wealth Advisors LLC Acquires 66 Shares of Danaher Co. (NYSE:DHR)

Meadow Creek Wealth Advisors LLC raised its holdings in shares of Danaher Co. (NYSE:DHR) by 3.4% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,021 shares of the conglomerate’s stock after acquiring an additional 66 shares during the quarter. Meadow Creek Wealth Advisors LLC’s holdings in Danaher were worth $562,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Good Life Advisors LLC bought a new stake in Danaher during the third quarter valued at about $217,000. Oak Thistle LLC bought a new stake in shares of Danaher in the second quarter worth about $363,000. Norden Group LLC bought a new stake in shares of Danaher in the first quarter worth about $4,151,000. Duality Advisers LP bought a new stake in shares of Danaher in the first quarter worth about $5,573,000. Finally, Investment Research & Advisory Group Inc. bought a new stake in shares of Danaher in the first quarter worth about $1,186,000. 79.05% of the stock is owned by institutional investors.

Danaher Stock Down 1.9 %

Danaher stock opened at $256.29 on Wednesday. The business has a fifty day moving average of $270.67 and a two-hundred day moving average of $260.46. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33. The firm has a market cap of $189.83 billion, a P/E ratio of 43.99, a P/E/G ratio of 4.49 and a beta of 0.83. Danaher Co. has a twelve month low of $182.09 and a twelve month high of $281.70.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. The company had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. Danaher’s revenue was up 3.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.02 earnings per share. On average, analysts forecast that Danaher Co. will post 7.59 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Friday, September 27th will be given a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.42%. The ex-dividend date is Friday, September 27th. Danaher’s payout ratio is presently 18.31%.

Insider Transactions at Danaher

In other news, SVP Brian W. Ellis sold 9,600 shares of the company’s stock in a transaction on Thursday, July 25th. The stock was sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the transaction, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at approximately $5,566,486.80. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, SVP Brian W. Ellis sold 9,600 shares of the company’s stock in a transaction on Thursday, July 25th. The stock was sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the transaction, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at approximately $5,566,486.80. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Rainer Blair sold 9,007 shares of the company’s stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total value of $2,521,960.00. Following the transaction, the chief executive officer now directly owns 97,983 shares in the company, valued at approximately $27,435,240. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 39,659 shares of company stock valued at $11,042,433. Corporate insiders own 11.10% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the company. Leerink Partners lifted their target price on Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a report on Wednesday, July 24th. Evercore ISI lifted their target price on Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Royal Bank of Canada reissued an “outperform” rating and set a $300.00 price objective on shares of Danaher in a research note on Friday, September 6th. Robert W. Baird reduced their price objective on Danaher from $278.00 to $277.00 and set an “outperform” rating on the stock in a research note on Wednesday. Finally, Bank of America boosted their price objective on Danaher from $270.00 to $275.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 24th. Seven investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $282.65.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.